Suchergebnisse - "Rimassa, Lorenza"

PubPharm (44)

1

A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence : PURITY study

enthalten in: BMC cancer | 2024

von Niger, M. | Nichetti, F. | Fornaro, L. | +34

2

Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

enthalten in: Journal of hepatology | 2024

von Celsa, C. | Cabibbo, G. | Fulgenzi, C. | +69

3

Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma : a multicentre retrospective study

enthalten in: The Lancet. Oncology | 2023

von Zeng, Q. | Klein, C. | Caruso, S. | +119

4

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy : A global, observational study

enthalten in: Hepatology communications | 2023

von Joerg, V. | Scheiner, B. | D Alessio, A. | +33

5

Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma : a multicenter real-world study

enthalten in: Journal of cancer research and clinical oncology | 2023

von Persano, M. | Rimini, M. | Tada, T. | +77

6

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01) : a multicentre, single-arm, phase 2b study

enthalten in: The Lancet. Oncology | 2023

von Harding, J. | Fan, J. | Oh, D. | +61

7

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma : a large real-life worldwide population

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Casadei-Gardini, A. | Rimini, M. | Tada, T. | +80

8

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : a multicentre, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2022

von Kelley, R. | Rimassa, L. | Cheng, A. | +19

CommentIn: Lancet Oncol. 2022 Aug;23(8):962-963. - PMID 35798015

9

Outcome of liver cancer patients with SARS-CoV-2 infection : An International, Multicentre, Cohort Study

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2022

von Muñoz-Martínez, S. | Sapena, V. | Forner, A. | +52

10

Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC

enthalten in: Hepatology communications | 2022

von Sharma, R. | Pillai, A. | Marron, T. | +26

1
2
3
4
5
Nächster »
[5]